# Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Source: https://onco.cc/trials/nct05281471/  
OnCo record `nct05281471` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Olvimulogene nanivacirepvec in ovarian cancer, now recruiting.

## Summary

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) is a phase 3 interventional study registered as NCT05281471, led by Genelux with GOG Foundation, and recruiting on the registry. Official title: A Randomised Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076). Planned enrolment is 186 participants (estimated). The study started in 2022-08-31 and primary completion is expected in 2026-12. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT05281471
- Phase: 3
- Setting: A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Sponsor: Genelux
- Enrolled: 186

## Sources

- ClinicalTrials.gov NCT05281471: https://clinicaltrials.gov/study/NCT05281471

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- drugs: [Olvimulogene nanivacirepvec](https://onco.cc/drugs/olvimulogene-nanivacirepvec/)
- companies: [Genelux](https://onco.cc/companies/genelux/)

---
JSON: https://onco.cc/api/v1/entities/nct05281471.json